Abatacept for SLE Arthritis (IM101-330)

NCT02429934 | Terminated Phase 1 Results DMC

• 1 other identifier: IM101-330 SLE Arthritis
• Study Type: interventional
• Target: 28
• Locations: 1 country
• Sites: 2

Brief Summary

This research trial is for patients who have been diagnosed with systemic lupus erythematosus (SLE) with swollen, tender joints (which is called inflammatory polyarthritis) because of the SLE. The purpose of this clinical research study is to evaluate the safety and effectiveness of treatment with abatacept (Abatacept) 125mg injected subcutaneously (under the skin) weekly for 16 weeks versus placebo injections(a substance with no active ingredients and therefore may have no treatment benefit) in subjects with SLE and inflammatory polyarthritis. The effectiveness will be assessed primarily by the number of swollen, tender joints (called a joint count) at each of study visits. Study Medication Abatacept is approved in the U.S. for treating rheumatoid arthritis by prescription and has not been approved by the U.S. Food and Drug Administration for treating SLE yet. In this study, subjects will receive treatment with either abatacept or placebo once a week for 16 weeks (a total of 16 injections).

Conditions

Systemic Lupus Erythematosus Arthritis

Keywords

Systemic Lupus Erythematosus (SLE); Abatacept (Orencia); Arthritis

Outcome Measures

Primary Outcomes (1)

• Number of Participants With at Least a 20% Improvement From Baseline in Tender and Swollen 28 Joint Count

  Assessed by physical exam. Total number of joints that are both swollen and tender were assessed in each participant by a physician at each study visit.

  Baseline, 8 Weeks, 16 Weeks

Secondary Outcomes (9)

• Change in SLEDAI 2K

  Baseline, 16 weeks

• Change in the PGA Score

  Baseline, 16 weeks

• Clinical Disease Activity Index (CDAI) Index Score

  16 weeks

• Synovitis, Tenosynovitis and Erosions Scores (GSUS and PDUS)

  Baseline, 16 weeks

• Number of AEs and SAEs

  16 weeks

Study Arms (2)

Abatacept also known as Orencia also known as CTLA4Ig

ACTIVE COMPARATOR

32 SLE patients to be treated with subcutaneous abatacept 125mg sq once a week for 16 weeks.

Biological: abatacept also known as Orencia also known as CTLA4-Ig

Placebo

PLACEBO COMPARATOR

32 SLE patients to be treated with subcutaneous placebo once a week for 16 weeks. Injection will be vehicle injected subcutaneously once a week for 16 weeks

Drug: Placebo

Interventions

abatacept also known as Orencia also known as CTLA4-Ig BIOLOGICAL

125mg injected subcutaneously weekly for 16 weeks

Also known as: Orencia

Abatacept also known as Orencia also known as CTLA4Ig

Placebo DRUG

Placebo

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Meet at least 4 of the 11 American College of Rheumatology (ACR) 1997 criteria for classification of SLE (see Appendix 1).OR meet the recent classification recommended by SLICC (Appendix 2) 6
• ≥3 swollen and tender joints on 2 examinations at least 2 weeks apart and no more than 8 weeks apart.
• SLEDAI2K score ≥4 indicating active disease.
• Documented positive ANA (≥1:80) and/or anti-dsDNA during course of SLE.
• Men and women, at least 18 years of age. Women of childbearing potential must use adequate method(s) of contraception to avoid pregnancy throughout the study and for up to 2 months after last study drug dose. They must have a negative serum or urine pregnancy test prior to the start of study medication.
• Background therapies allowed: antimalarials (dose constant for ≥ one month before study entry and during 16 weeks of trial), methotrexate (same criteria as for antimalarials), azathioprine (same criteria), mycophenolate (same criteria), leflunomide (same criteria).
• During the screening period and for up to 6 weeks after randomization, a daily prednisone (or equivalent) regimen of up to 20 mg daily may be initiated to treat the moderate to severe disease activity present at screening. The initial steroid regimen is not required if investigators or patients believe that the risks would outweigh the potential benefits. Patients who do not take any glucocorticoids during the study will be included in the treatment groups and analysis.
• \*Steroids should be tapered to a target dose of no more than 10 mg/day of prednisone (or equivalent) by the end of Week 8 (Day 56). The steroid regimen should be tapered as quickly as safely possible. Prednisone dose requirements higher than 10 mg daily at the 8 week visit will cause the patient to be ruled a non-responder for the abatacept treatment arm.

You may not qualify if:

• Subjects with active infection requiring oral or IV antibiotics within one month of first dose of study medication.
• Subjects with BILAG A in any system outside the musculoskeletal system.
• Subjects with positive quantiferon Gold test in the absence of treatment for tuberculosis.
• Subjects with positive tests for active infection with hepatitis B or C during the past 6 months. Any confirmed positive test for HIV at any time prior to entry into this study.
• Subjects with active glomerulonephritis (\>3 g protein/24h and/or active urine sediment).
• Subjects with active CNS disease.
• Subjects with any other serious disease that would require immunosuppressive or parenteral anti-microbial therapy outside the study protocol.
• Inability to self-administer subcutaneous injections, to comply with instructions, or to keep appointments for study visits.
• Treatment with rituximab within the past 6 months (B cells must be detectable in peripheral blood at onset of treatment with study biologic), belimumab within the past 5 months, cyclophosphamide within the past 3 months.
• Treatment with any other immunomodulatory biologic or cyclophosphamide during treatment with abatacept is not allowed.
• Patients requiring \>20 mg of prednisone daily.
• Women who are pregnant or breast feeding.
• Women of child bearing potential unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period and for up to 2 months after last study drug.
• Subjects with a history of cancer within the last five years (other than non-melanoma skin cell cancers cured by local resection).
• Any laboratory test results that, in the opinion of the Investigator, might place the subject at unacceptable risk for participation in this study.

Sponsors & Collaborators

• University of California, Los Angeles: lead
• Bristol-Myers Squibb: collaborator

Study Sites (2)

UCLA David Geffen School of Medicine, Division of Rheumatology

Los Angeles, California, 90095, United States

Location

University of California, San Diego

San Diego, California, 92093, United States

Location

MeSH Terms

Conditions

Lupus Erythematosus, Systemic; Arthritis

Interventions

Abatacept

Condition Hierarchy (Ancestors)

Connective Tissue Diseases; Skin and Connective Tissue Diseases; Autoimmune Diseases; Immune System Diseases; Joint Diseases; Musculoskeletal Diseases

Intervention Hierarchy (Ancestors)

Immunoconjugates; Antibodies; Immunoglobulins; Serum Globulins; Blood Proteins; Proteins; Amino Acids, Peptides, and Proteins; Globulins

Results Point of Contact

• Title: Dr. Bevra Hahn
• Organization: University of California at Los Angeles

bhahn@mednet.ucla.edu

8184869745

Study Officials

• Bevra Hahn, M.D.

  University of California, Los Angeles

  PRINCIPAL INVESTIGATOR

Publication Agreements

• PI is Sponsor Employee: No
• Restriction Type: LTE60
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 24, 2015
• First Posted: April 29, 2015
• Study Start: October 1, 2015
• Primary Completion: September 1, 2019
• Study Completion: September 1, 2019
• Last Updated: May 13, 2021
• Results First Posted: May 13, 2021

Record last verified: 2021-05

Locations

US (2)